Clinical stage biotechnology company focusing on research, development and commercialization of psychedelic pharmaceuticals PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) says that it has started phase 2 KET-LID clinical trial of ketamine for the treatment of Parkinson’s disease.
The Ketamine will be used in treatment of Levedopa-induced Dyskinesia with respect to Parkinson’s disease. The company says patients screening and enrollment for the trials will commence this month with data expected before the year wraps up.
The phase 2 KET-LID clinical trials will be a randomized, double-blind, active placebo controlled research to find out the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients suffering from Parkinson’s disease.
Back in May, PhamaTher said an IND for the trials had been approved by the United States Food and Drug Administration (FDA). If the phase 2 clinical trial is positive, PharmaTher will request for a meeting with the FDA to advance to a Phase 3 clinical trials.
“Initiation of the Phase 2 clinical trial of ketamine to treat Parkinson’s disease, or the KET-LID trial, is a significant milestone for PharmaTher and we are excited about the opportunity to advance a potential new therapeutic solution for Parkinson’s disease patients,” said the company’s CEO, Fabio Chianelli.